Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 30;30(1):218–228. doi: 10.1038/s41591-023-02660-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 10 — a, Patients with LN involvement by imaging at baseline and by pathology at resection by treatment arm. b, Radiographic (BOR per RECIST1.1) and pathologic response (%RVT) in PT. c, Radiographic (BOR per RECIST1.1) and pathologic response (%RVT) in LN, across treatment arms. d, Radiographic (BOR per RECIST1.1) and pathologic response (%RVT) in LN by treatment arm. e, ctDNA clearance and pathologic response (%RVT) in PT. f, ctDNA clearance and pathologic response (%RVT) in LN, across treatment arms. g, ctDNA clearance and pathologic response (%RVT) in LN by treatment arm. BOR denotes best overall response; CR complete response; LN, lymph node; MPR, major pathologic response; NE, not evaluable; pCR, pathologic complete response; PD, progressive disease; PR, partial response; PT, primary tumor; RECIST1.1, Response Evaluation Criteria in Solid Tumors version 1.1; RVT, residual viable tumor; SD, stable disease. ^aData were not reported for 1 patient. ^bctDNA data were not available/not evaluable for 108 patients. ^cctDNA data were not available/not evaluable for 93 patients. ^dctDNA data were not available/not evaluable for 109 patients. ^ectDNA data were not available/not evaluable for 53 patients. ^fctDNA data were not available/not evaluable for 56 patients.